Management and Outcomes of Relapse After Treatment for Thymoma and Thymic Carcinoma

被引:45
|
作者
Bott, Matthew J.
Wang, Hanghang
Travis, William
Riely, Gregory J.
Bains, Manjit
Downey, Robert
Rusch, Valerie
Huang, James [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Thorac Serv, Dept Surg, Dept Pathol, New York, NY 10065 USA
来源
ANNALS OF THORACIC SURGERY | 2011年 / 92卷 / 06期
关键词
CLINICOPATHOLOGICAL FEATURES; STAGE-III; FOLLOW-UP; RECURRENCE; CHEMOTHERAPY; REOPERATION; RESECTION; THERAPY; TUMORS;
D O I
10.1016/j.athoracsur.2011.07.078
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Although surgery is the mainstay of treatment for thymic tumors, recurrence is common despite resection. The optimal approach to the management of disease relapse after treatment for thymic tumors remains unclear. Methods. This study is a retrospective analysis of a single-institution experience assessing treatment patterns and outcomes in patients with recurrence or disease progression after surgical treatment for thymic tumors. Data included demographics, stage, treatment, pathologic findings, and postoperative outcomes. Results. From 1995 to 2006, 120 patients had initial resection of a thymic tumor at our institution, of which 112 had recurrence data available. Twenty-five patients developed recurrence or progression of disease after their initial resection (10 thymic carcinoma, 15 thymoma). Median follow-up was 51.4 months. Higher Masaoka stages predominated (I: 0; II: 4; III: 8; IV: 13). Eleven patients (44%) underwent surgery for their relapse with curative intent, while 14 (56%) were managed nonsurgically. Surgery was considered when disease was intrathoracic, unilateral, and technically resectable. The 11 patients receiving surgery had a total of 16 reoperations (range 1 to 4). An R0 re-resection was obtained in half of cases (8 of 16, 50%) but the majority of operative patients (9 of 11, 82%) recurred again. The 5-year overall survival of the 25 patients with recurrent or persistent disease was 58% (median survival = 82 months). Kaplan-Meier curves demonstrate a trend (p = 0.08) toward improved overall survival in patients treated with surgery versus those treated nonoperatively (median survival = 156 months versus 50 months). Patients with thymoma demonstrated a trend (p = 0.12) toward improved survival for over thymic carcinoma (median survival = 90 months versus 35 months). Conclusions. Treatment of patients with recurrent or progressive thymic tumors is associated with long-term survival. Despite the historical enthusiasm for re-resection, the majority of patients will recur again, therefore reoperation should be considered only in selected patients.
引用
收藏
页码:1984 / 1992
页数:9
相关论文
共 50 条
  • [21] Staging of thymic epithelial neoplasms: Thymoma and thymic carcinoma
    Weissferdt, Annikka
    Moran, Cesar A.
    PATHOLOGY RESEARCH AND PRACTICE, 2015, 211 (01) : 2 - 11
  • [22] Thymic Squamous Carcinoma Coexisting with Thymoma
    Alici, Ibrahim Onur
    Yilmaz, Aydin
    Demirci, Nilgn Yilmaz
    Demirag, Funda
    Aydogdu, Koray
    Turay, Ulku Yilmaz
    Biber, Cigdem
    Erdogan, Yurdanur
    Kaya, Sadi
    EURASIAN JOURNAL OF PULMONOLOGY, 2012, 14 (02) : 113 - 116
  • [23] Immune profile of thymoma and thymic carcinoma
    Yamamoto, Yoko
    Iwahori, Kota
    Kanzaki, Ryu
    Funaki, Soichiro
    Shintani, Yasushi
    Okumura, Meinoshin
    Wada, Hisashi
    CANCER SCIENCE, 2018, 109 : 1331 - 1331
  • [24] Novel Treatments for Thymoma and Thymic Carcinoma
    Rajan, Arun
    Wakelee, Heather
    Giaccone, Giuseppe
    FRONTIERS IN ONCOLOGY, 2015, 5
  • [25] Thymoma and Thymic Carcinoma - Our Experience
    Kuliskova, Jana
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1005 - S1005
  • [26] Molecular pathology of thymoma and thymic carcinoma
    Suster, David I.
    Basu, Malay Kumar
    Mackinnon, A. Craig
    JOURNAL OF CANCER METASTASIS AND TREATMENT, 2022, 8
  • [27] Transcriptomic difference of thymoma and thymic carcinoma
    Liang, N.
    Liu, L.
    Liu, H.
    Wang, W.
    Bi, Y.
    Liang, Z.
    Li, N.
    Lin, R.
    Wang, T.
    Li, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [28] Imaging Evaluation of Thymoma and Thymic Carcinoma
    Strange, Chad D.
    Ahuja, Jitesh
    Shroff, Girish S.
    Truong, Mylene T.
    Marom, Edith M.
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [29] Genetic analysis of thymoma and thymic carcinoma
    Yamaguchi, Hiroyuki
    Gyotoku, Hiroshi
    Taniguchi, Hirokazu
    Sasaki, Daisuke
    Shimada, Midori
    Dotsu, Yosuke
    Senju, Hiroaki
    Kaku, Norihito
    Ikeda, Takaya
    Fukuda, Minoru
    Yanagihara, Katsunori
    Mukae, Hiroshi
    CANCER RESEARCH, 2019, 79 (13)
  • [30] Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens
    Ma, Wei-Li
    Lin, Chia-Chi
    Hsu, Feng-Ming
    Lee, Jang-Ming
    Chen, Jin-Shing
    Huang, Yen-Lin
    Chang, Yih-Leong
    Chang, Chin-Hao
    Yang, James Chih-Hsin
    CANCER MEDICINE, 2022, 11 (18): : 3445 - 3456